Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.00 (-0.01%)
Close on Nov 13, 2026Market cap $58.23MP/E –Yield –
Earnings
Spero Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
$0.76
-$0.13 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Spero Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | $0.76 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026during market hours | – | – | -$0.16 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | $300.00K | -94.9% | -$0.13 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026during market hours | $41.30M | +175.3% | $0.53 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025during market hours | $5.40M | – | -$0.13 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025during market hours | $14.20M | +39.2% | -$0.03 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025during market hours | $5.90M | -36.6% | -$0.25 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025during market hours | $15.00M | -79.6% | -$0.38 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 29, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024during market hours | $10.20M | +277.8% | -$0.33 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024during market hours | $9.30M | +342.9% | -$0.24 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024during market hours | $73.50M | +55.1% | $0.96 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | $25.50M | +1175.0% | -$0.06 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023during market hours | $2.70M | +35.0% | -$0.23 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | $2.10M | 0.0% | -$0.25 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023during market hours | $47.40M | +1655.6% | $0.55 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022during market hours | $2.00M | -35.5% | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | $2.00M | – | -$0.87 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022during market hours | $2.10M | – | -$1.01 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022during market hours | $2.70M | – | -$0.90 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021during market hours | $3.10M | – | -$0.70 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 11, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Spero Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Spero Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Spero Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
See a number that looks wrong?